• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Taysha Gene Therapies Inc.

    4/22/26 8:02:49 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TSHA alert in real time by email
    DEFA14A 1 d139508ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.)

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    Taysha Gene Therapies, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the Notice and Proxy Statement and Annual Report, and to obtain directions to attend the meeting, go to: www.ProxyVote.com. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS, TEXAS 75247 V90327-P46595 Your Vote Counts! TAYSHA GENE THERAPIES, INC. 2026 Annual Meeting Vote in advance by May 31, 2026 11:59 PM ET You invested in TAYSHA GENE THERAPIES, INC. and it’s time to vote! Stockholders of record as of the close of business on April 8, 2026 have the right to vote on proposals being presented at the 2026 Annual Meeting. THIS IS AN IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON JUNE 1, 2026. Get informed before you vote View the Annual Report and Notice and Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 18, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and June 1, 2026 9:00 AM Eastern Time vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/TSHA2026 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1. To elect the Board’s Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders. Nominees: For 01) Sean P. Nolan 02) Laura Sepp-Lorenzino, Ph.D. 2. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent For registered public accounting firm of the Company for the year ending December 31, 2026. 3. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers. For 4. To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the 1 Year compensation of the Company’s named executive officers. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment, continuation, or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V90328-P46595

    Get the next $TSHA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TSHA

    DatePrice TargetRatingAnalyst
    10/21/2025$13.00Strong Buy
    Raymond James
    7/11/2025$8.00Buy
    BofA Securities
    6/27/2024$5.00Outperform
    BMO Capital Markets
    4/9/2024$9.00Overweight
    Piper Sandler
    2/1/2023$14.00 → $1.50Buy → Hold
    Jefferies
    1/27/2023$23.00 → $3.00Overweight → Equal-Weight
    Morgan Stanley
    11/9/2022$16.00 → $3.00Buy → Neutral
    Goldman
    3/9/2022$26.00Outperform
    Robert W. Baird
    More analyst ratings

    $TSHA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Manning Paul B bought $2,062,500 worth of shares (750,000 units at $2.75) (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    6/3/25 9:38:27 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Manning Paul B bought $2,999,999 worth of shares (1,333,333 units at $2.25) (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    7/1/24 8:00:07 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Manning Paul B bought $163,000 worth of shares (100,000 units at $1.63) (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    11/20/23 7:35:02 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    DALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies,

    4/3/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

    Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of ≥3 months of safety data in planned BLA submission to support potential for broad label; on track to complete dosing in Q2 2026 Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026 data cutoff; longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials expected in Q2 2026 Reached written alignment with FDA on proposed PPQ

    3/19/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com. An archived replay of the webcast will be available on

    3/12/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Nagendran Sukumar

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    4/13/26 4:33:58 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF FINANCIAL OFFICER Alam Kamran sold $7,481 worth of shares (1,655 units at $4.52), decreasing direct ownership by 0.11% to 1,442,131 units (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    2/6/26 4:30:29 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and Head of R&D Nagendran Sukumar sold $547,469 worth of shares (116,050 units at $4.72), decreasing direct ownership by 8% to 1,317,389 units (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    1/27/26 4:05:16 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Taysha Gene Therapies Inc.

    DEFA14A - Taysha Gene Therapies, Inc. (0001806310) (Filer)

    4/22/26 8:02:49 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Taysha Gene Therapies Inc.

    DEF 14A - Taysha Gene Therapies, Inc. (0001806310) (Filer)

    4/22/26 8:01:44 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Taysha Gene Therapies Inc.

    144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    4/10/26 4:11:05 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Taysha Gene Therapies with a new price target

    Raymond James initiated coverage of Taysha Gene Therapies with a rating of Strong Buy and set a new price target of $13.00

    10/21/25 7:22:35 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Taysha Gene Therapies with a new price target

    BofA Securities initiated coverage of Taysha Gene Therapies with a rating of Buy and set a new price target of $8.00

    7/11/25 8:16:08 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BMO Capital Markets initiated coverage on Taysha Gene Therapies with a new price target

    BMO Capital Markets initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $5.00

    6/27/24 7:52:29 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Financials

    Live finance-specific insights

    View All

    Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

    Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of ≥3 months of safety data in planned BLA submission to support potential for broad label; on track to complete dosing in Q2 2026 Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026 data cutoff; longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials expected in Q2 2026 Reached written alignment with FDA on proposed PPQ

    3/19/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com. An archived replay of the webcast will be available on

    3/12/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which was enabled by the rigorous developmental milestone evaluation in Part A REVEAL Phase 1/2 trials showing an unprecedented response rate Dosing of first patient in REVEAL pivotal trial scheduled for Q4 2025, with enrollment of additional patients expected to continue at multiple sites this quarter Presented new supplemental analysis of Part A REVEAL data reinforcing the broad and consistent, multi-domain impact of TSHA-102 on activities of daily living at the CNS Annual Meeting TSHA-102

    11/4/25 7:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Leadership Updates

    Live Leadership Updates

    View All

    Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update

    DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the full-year ended December 31, 2020 and provided a corporate update. “In 2020, we successfully completed one of the fastest seed to IPOs in biotech history and made significant strides in advancing our pipeline initiatives, next-generation technology platforms and manufacturing strategy,” said RA Session II, President, Founder and CEO o

    3/3/21 7:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer

    DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced new additions to its leadership team with the appointments of Timothy J. Douros, J.D., as Chief Legal Officer and Corporate Secretary and Tracy M. Porter, M.Ed., SPHR, as Chief People Officer. Mr. Douros will lead all aspects of the company’s legal organization. Ms. Porter will oversee all aspects of human resources, including operations, talent acquisition and employee development.

    1/26/21 7:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 5:51:11 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 5:46:12 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Taysha Gene Therapies Inc.

    SC 13G - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 9:40:52 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care